When was ARTMS founded?

ARTMS was founded in 2013 and raised its 1st funding round 4 years after it was founded.

Where is ARTMS located?

ARTMS is headquartered in Vancouver, Canada.

How many employees does ARTMS have?

As of Jun 30, 2026, the latest employee count at ARTMS is 30.

Is ARTMS a funded company?

ARTMS is a funded company, having raised a total of $26.6M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2017.

When was the latest funding round of ARTMS?

ARTMS's latest funding was a $***** Grant (prize money) round on Feb 24, 2021, with participation from 1 investor.

Where does ARTMS rank among its competitors?

ARTMS ranks 3rd amongst 28 active competitors, of which 6 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was NorthStar Medical Radioisotopes, which secured $10.7M in May, 2025.

Who are the top competitors of ARTMS?

ARTMS's top competitors include Curium, NorthStar Medical Radioisotopes and AZI. Among them, NorthStar Medical Radioisotopes secured the most recent funding round in May, 2025.

ARTMS - 2026 Company Profile, Team, Funding & Competitors

ARTMS is an acquired company based in Vancouver (Canada), founded in 2013. It operates as a Provider and developer of radioisotope technologies. ARTMS has raised $26.6M in funding from Deerfield and Quark Venture. The company has 28 active competitors, including 6 funded and 4 that have exited. Its top competitors include companies like Curium, NorthStar Medical Radioisotopes and AZI.

Company Details

ARTMS is a developer of radioisotope technologies. The company offers technological services to enable the development of radioisotope technologies. The flagship product QIS enables turnkey production of purified radiometals by radioisotope material developers.

Website: artms.ca
Social
Email ID: *****@artms.ca
Phone Number: +1 **********

Key Metrics

Founded Year

2013

Location

Vancouver, Canada

Stage

Acquired

Total Funding

$26.6M in 5 rounds

Latest Funding Round

Grant (prize money), Feb 24, 2021, $*****

Investors

Deerfield & 4 more

Ranked

3^rd among 28 active competitors

Employee Count

30 as on Jun 30, 2026

Similar Companies

Curium & 31 more

Exit Details

Acquired by Telix Pharma (Mar 05, 2024)

View ARTMS's full profile

ARTMS got acquired by Telix Pharma on Mar 05, 2024.

Click here to take a look at ARTMS's acquisition in detail

ARTMS has raised a total funding of $26.6M over 5 rounds. Its first funding round was on 2017. Its latest funding round was a Grant (prize money) round on Feb 24, 2021 for $*****. 1 investor participated in its latest round. ARTMS has 5 institutional investors.

Here is the list of recent funding rounds of ARTMS:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 24, 2021	7570039	Grant (prize money)	3505083	4330898	9398511	3486623
May 13, 2020	8866279	Series A	6020153	5192109	7631805	Quark Venture & 1 more
Aug 14, 2019	8181533	Series A	5067572	9496146	2653760	Canadian Space Agency

Access funding benchmarks and valuations. Sign up today!

View details of ARTMS's funding rounds and investors

ARTMS's employee count trend

ARTMS has 30 employees as of Jun 26. Here is ARTMS's employee count trend over the years:

Uncover ARTMS's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ARTMS include Curium, NorthStar Medical Radioisotopes and AZI. Here is the list of Top 10 competitors of ARTMS, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Curium 2017, Paris (France), Seed	Specialty developer, manufacturer & distributor of radiopharmaceuticals	-	CapVest, Ardian	62/100
2nd	NorthStar Medical Radioisotopes 2006, Madison (United States), Series B	Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market	$15.1M	Hendricks Holding, Stateline Angels & 4 others	58/100
3rd	ARTMS 2013, Vancouver (Canada), Acquired	Provider and developer of radioisotope technologies	$26.6M	Deerfield, GF Securities & 3 others	46/100
4th	AZI 2017, Bunker Hill (United States), Series C	Developer of radiopharmaceuticals for imaging purposes	$58.3M	-	42/100
5th	ATOMIC ALCHEMY 2017, Idaho Falls (United States), Acquired	Limited information available	$150K	Y Combinator, Hemisphere Ventures	39/100
6th	Ground Fluor Pharmaceuticals 2012, Lincoln (United States), Series A	Biomedical company developing proprietary new chemistry for the synthesis of pharmaceutical compounds	-	Nebraska, National Science Foundation & 2 others	37/100
7th	CellBion 2010, Seoul (South Korea), Public	Radioactive probes for imaging	-	M Venture Investment, BNH INVESTMENT & 2 others	33/100
8th	Am Chemicals 2003, Oceanside (United States), Unfunded	Oligonucleotide synthesis solutions: solid supports, reagents, and expert services	-	-	33/100
9th	Nanovista 2015, Toronto (Canada), Seed	Developing multimodal visualization agents	$2.3M	JLABS, GreenSky	32/100
10th	Alsachim 2005, Illkirch Graffenstaden (France), Acquired	Custom synthesis of stable radioisotopes & analytical services for pharmaceutical and biotech companies	-	Naxicap	31/100